Special Issue

Interferon Responses after Vaccine Administration

Message from the Guest Editors

Interferons (IFNs) are a family of proteins that cells exhibiting productive effects in response to infection or other stressors. They play a critical role in immune responses by activating antiviral defenses, stimulating the production of antibodies, and recruiting immune cells to the site of infection. The role of IFNs in the immune response to vaccines is becoming increasingly recognized. IFNs can enhance the production of antibodies and other immune responses to vaccines, and they can also help to protect against vaccine-preventable diseases. The articles in this Special Issue will explore the latest research on the role of IFNs in the immune response to vaccines. They will discuss how IFNs interact with other components of the immune system, how IFNs can be used to improve the efficacy of vaccines, and the safety and efficacy of IFNs in vaccine development. This special issue will be of interest to researchers and clinicians working in the fields of immunology, vaccinology, and infectious diseases.

Guest Editors

Dr. Luis Ignacio González-Granado
University Hospital 12 Octubre, Complutense University of Madrid, Madrid, Spain

Dr. Hugh Thomson Reyburn
CSIC-Centro Nacional de Biotecnologia (CNB), Madrid, Spain

Deadline for manuscript submissions

closed (31 July 2024)

Vaccines

an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed

mdpi.com/si/185591

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

mdpi.com/journal/vaccines

Vaccines

an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed

mdpi.com/journal/vaccines

About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp
Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).

MDPI